Myths vs facts: CYP1A2 and longevity

The claim that CYP1A2 variants directly affect longevity is not well supported by current evidence. CYP1A2 primarily influences caffeine metabolism. Some observational studies suggest a link between caffeine intake and reduced risk of certain diseases, but effect sizes are small and confounded by lifestyle. Most associations come from GWAS or epidemiological data, not from interventional trials. Consumer DNA tests (e.g., MyBody-X) report SNPs like rs762551, but their predictive value for lifespan is negligible. No robust evidence shows that CYP1A2 genotype alone significantly impacts longevity. Diet, exercise, and smoking are far more influential. Therefore, labeling a CYP1A2 variant as a 'longevity marker' is more myth than fact. The evidence is unclear and largely mechanistic, not clinically validated.